Following the successful development and rapid roll-out of its COVID-19 vaccine, Moderna (Nasdaq: MRNA) has wasted no time in seeking to prove that it is not a one-trick pony.
The US mRNA company’s pipeline of vaccines and therapeutics is full of wider potential, targeting everything from flu, respiratory syncytial virus (RSV), cytomegalovirus, HIV, cancer, lyme diseases, Zi ka and more.
Another disease that Moderna is committed to tackling is hMPV, formally human metapneumovirus, which can cause severe infections and is particularly dangerous for young children, older adults, and people with weakened immune systems. It is a relative to RSV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze